Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Biotechnology entrepreneurship--where no research has gone before.

Salgaller ML, Marincola FM.

J Transl Med. 2010 Oct 15;8:102. doi: 10.1186/1479-5876-8-102. No abstract available.

2.

Current status of clinical trials for glioblastoma.

Salgaller ML, Liau LM.

Rev Recent Clin Trials. 2006 Sep;1(3):265-81. Review.

PMID:
18473979
3.

AACR - 91st meeting. Satellite meeting - immunotherapy of cancer.

Salgaller ML.

IDrugs. 2000 Jul;3(7):719-22. No abstract available.

PMID:
16080034
4.

AACR - 91st meeting. Dendritic cell vaccine strategies.

Salgaller ML.

IDrugs. 2000 Jul;3(7):714-6.

PMID:
16080032
5.

Immunosuppressive factors in the tumor environment: Potential implications for immune-based therapies.

McEarchern JA, Salgaller ML.

IDrugs. 2001 Feb;4(2):197-205. No abstract available.

PMID:
16032482
6.

92nd AACR. Immunotherapy of cancer.

Salgaller ML.

IDrugs. 2001 May;4(5):501-3. No abstract available.

PMID:
16012883
7.

Therapeutic potential of dendritic-based vaccines.

Jones LA, Salgaller ML.

Expert Opin Investig Drugs. 1999 Jul;8(7):1007-16.

PMID:
15992102
8.

Advances in oncology--cancer immunology.

Salgaller ML.

IDrugs. 2001 Dec;4(12):1343-5. No abstract available.

PMID:
15931561
9.

Advances in oncology--clinical advances and molecular oncology.

Salgaller ML.

IDrugs. 2001 Dec;4(12):1339-42. No abstract available.

PMID:
15931560
10.

Technology evaluation: bevacizumab, Genentech/Roche.

Salgaller ML.

Curr Opin Mol Ther. 2003 Dec;5(6):657-67.

PMID:
14755893
11.

Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses.

Zhou Y, McEarchern JA, Howard E, Pestano G, Salgaller ML, Bosch ML.

Cancer Immunol Immunother. 2003 Jul;52(7):413-22. Epub 2003 Feb 15.

PMID:
12835918
12.

A manifesto on the current state of dendritic cells in adoptive immunotherapy.

Salgaller ML.

Transfusion. 2003 Apr;43(4):422-4. Review. No abstract available.

PMID:
12662272
13.

Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity.

Zhou Y, Bosch ML, Salgaller ML.

J Immunother. 2002 Jul-Aug;25(4):289-303. Review.

PMID:
12142552
14.

The development of immunotherapies for non-small cell lung cancer.

Salgaller ML.

Expert Opin Biol Ther. 2002 Mar;2(3):265-78. Review.

PMID:
11890866
15.

Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line.

Zhou Y, Toth M, Hamman MS, Monahan SJ, Lodge PA, Boynton AL, Salgaller ML.

Biochem Biophys Res Commun. 2002 Jan 18;290(2):830-8.

PMID:
11785977
16.

Viral vectors for gene transfer into antigen presenting cells.

Monahan SJ, Salgaller ML.

Curr Opin Mol Ther. 1999 Oct;1(5):558-64. Review.

PMID:
11249662
17.

Immune monitoring of cancer patients undergoing experimental immunotherapy.

Shankar G, Salgaller ML.

Curr Opin Mol Ther. 2000 Feb;2(1):66-73. Review.

PMID:
11249653
19.
20.

Dendritic cell-based immunotherapy for prostate cancer.

Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP.

CA Cancer J Clin. 1999 Mar-Apr;49(2):117-28, 65.

21.

Progress in active-specific immunotherapy of brain malignancies.

Tjoa BA, Salgaller ML.

Expert Opin Investig Drugs. 2000 Sep;9(9):2093-101. Review.

PMID:
11060795
22.

Prostate cancer immunotherapy at the dawn of the new millennium.

Salgaller ML.

Expert Opin Investig Drugs. 2000 Jun;9(6):1217-29. Review.

PMID:
11060738
23.

Immunologic approaches to antigen discovery for cancer vaccines.

Jones LA, Salgaller ML.

Expert Opin Investig Drugs. 2000 Mar;9(3):481-90. Review.

PMID:
11060689
24.

Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML.

Cancer Res. 2000 Feb 15;60(4):829-33.

25.

Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials.

Salgaller ML, Thurnher M, Bartsch G, Boynton AL, Murphy GP.

Cancer. 1999 Dec 15;86(12):2674-83. No abstract available.

PMID:
10594863
26.

Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells.

Lodge PA, Childs RA, Monahan SJ, McLean JG, Sehgal A, Boynton AL, Salgaller ML, Murphy GP.

J Immunother. 1999 Jul;22(4):346-55.

PMID:
10404436
27.
28.

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.

Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL.

Prostate. 1999 Apr 1;39(1):54-9.

PMID:
10221267
29.

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.

Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL.

Prostate. 1999 Jan 1;38(1):73-8.

PMID:
9973112
30.

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.

Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP.

Prostate. 1998 Jun 15;36(1):39-44.

PMID:
9650914
31.

Use of cellular and cytokine adjuvants in the immunotherapy of cancer.

Salgaller ML, Lodge PA.

J Surg Oncol. 1998 Jun;68(2):122-38. Review.

PMID:
9624043
32.

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA).

Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP.

Prostate. 1998 May;35(2):144-51.

PMID:
9568678
33.

Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes.

Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG.

Curr Eye Res. 1998 Feb;17(2):165-73.

PMID:
9523095
34.

Dendritic cell-based immunotherapy of prostate cancer.

Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP.

Crit Rev Immunol. 1998;18(1-2):109-19.

PMID:
9419453
35.

Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.

Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR.

Clin Exp Metastasis. 1997 Sep;15(5):509-18.

PMID:
9247253
36.

Expression of MAGE genes in ocular melanoma cell lines.

Chen PW, Murray TG, Salgaller ML, Ksander BR.

J Immunother. 1997 Jul;20(4):265-75.

PMID:
9220316
37.

Cancer immunotherapy for prostate cancer.

Tjoa BA, Erickson SJ, Bowes VA, Salgaller ML, Lodge PA, McLean JG, Ragde H, Kenny GM, Boynton AL, Murphy GP.

Can J Urol. 1997 Jun;4(2 Supp 1):79-82.

PMID:
12735843
38.

Monitoring of cancer patients undergoing active or passive immunotherapy.

Salgaller ML.

J Immunother. 1997 Jan;20(1):1-14. Review. No abstract available.

PMID:
9101409
39.

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM.

Cancer J Sci Am. 1997 Jan-Feb;3(1):37-44.

40.

Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.

Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, Steller MA.

Am J Obstet Gynecol. 1996 Dec;175(6):1586-93.

PMID:
8987945
41.

MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors.

Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T.

Int J Cancer. 1996 Oct 21;69(5):375-80.

42.

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA.

Cancer Res. 1996 Oct 15;56(20):4749-57.

43.

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y.

J Immunol. 1996 Sep 15;157(6):2539-48.

PMID:
8805655
44.

Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):266-77.

PMID:
8877721
45.

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM.

J Immunol. 1996 May 15;156(10):3882-91.

PMID:
8621927
46.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):192-205.

PMID:
8811494
47.

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.

Cancer Res. 1995 Nov 1;55(21):4972-9.

48.

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al.

J Immunol. 1995 Mar 1;154(5):2257-65.

PMID:
7868898
49.

Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.

Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA.

Cancer Immunol Immunother. 1994 Aug;39(2):105-16.

PMID:
7519125
50.

Baculovirus recombinants expressing the human carcinoembryonic antigen gene.

Salgaller ML, Bei R, Schlom J, Poole DJ, Robbins PF.

Cancer Res. 1993 May 1;53(9):2154-61.

Supplemental Content

Loading ...
Support Center